What is the 13F Pro Quality Score for WST?

13F Pro ranks WEST PHARMACEUTICAL SERVICES INC (WST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WST's current score at https://13fpro.ai/company/WST (free sign-up required for the full ranking).

Where does 13F Pro source WST data?

All WEST PHARMACEUTICAL SERVICES INC fundamentals and ownership data come directly from SEC EDGAR. WEST PHARMACEUTICAL SERVICES INC files with the SEC under CIK 105770. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WST in?

WEST PHARMACEUTICAL SERVICES INC (WST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives WST's revenue?

Per WEST PHARMACEUTICAL SERVICES INC's latest 10-Q filed with the SEC on 2026-07-23, the biggest revenue drivers are: Proprietary Products ($722.6M, +16.6% YoY); West Vantage ($149.7M, +2.0% YoY); HVP Components (49% of net sales, +18.4% organic (ex-FX)). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/WST.

How often is WST research updated on 13F Pro?

WST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

WEST PHARMACEUTICAL SERVICES INC(WST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 105770 WST stock profile & AI dashboard →

13F Pro Quality Score

64.4/100

Rank #545 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

50.4/100

Profitability

75.4/100

Balance Sheet

91.3/100

Earnings Quality

66.6/100

Free Cash Flow

62.0/100

Institutional Flow

34.3/100

Revenue Scale

71.5/100

Dilution Risk

64.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why WST Scores 64/100

exact factor attribution · 2026-09-11

WST's composite is driven by capital efficiency and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Capital efficiency

+4.1 pts

91th pct

Profitability

+3.8 pts

75th pct

Scale

+3.2 pts

72th pct

Free cash flow

+1.8 pts

62th pct

Earnings quality

+1.7 pts

67th pct

Shareholder dilution

+0.7 pts

64th pct

Revenue growth

+0.1 pts

50th pct

Earnings growth

-0.3 pts

45th pct

Institutional flow

-0.8 pts

34th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

WST Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for WEST PHARMACEUTICAL SERVICES INC (WST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WST at 64.4/100 on a 32-signal composite quality model, placing it at rank #545 of 2,961 stocks — the top 25% of the AI-ranked universe. WST scores in the top quartile across balance sheet strength (91.3), profitability (75.4). Areas of concern include institutional flow (34.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), WEST PHARMACEUTICAL SERVICES INC reports quarterly revenue of $872.3M, net income of $154.0M, an operating margin of 20.5%. Top institutional holders of WST by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. WST trades on the NYSE exchange and files with the SEC under CIK 105770. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for WEST PHARMACEUTICAL SERVICES INC directly from SEC EDGAR. WEST PHARMACEUTICAL SERVICES INC's 13F Pro composite quality score has ranged between 62 and 76 since 2021, currently 64.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about WEST PHARMACEUTICAL SERVICES INC

Quirks, history, and lore behind WST — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. industrial/healthcare company · mid-cap · listed on the NYSE · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of $3 billion, with operating margins that would make a pharma CFO nod approvingly — this is a high-precision, high-margin niche business.
3
The History
Founded in 1923, it spent a century quietly becoming the world's go-to supplier of containment and delivery components for injectable drugs — an unglamorous throne nobody else really wanted.
4
The Secret
Every time a vaccine or biologic gets filled into a vial, there's a good chance this company made the rubber stopper or plastic closure sealing it shut.
5
The Lore
COVID-19 vaccine rollouts sent its stock soaring as demand for drug-packaging components exploded — billions of doses means billions of stoppers, seals, and delivery systems.
6
The Giveaway
Its name sounds like a cowboy state meets a drugstore, and its little rubber stoppers sit on top of nearly every injectable medication on the planet.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving WST's Business? Latest 10-Q Breakdown

✓ 26/26 datapoints verified

AI-extracted from WEST PHARMACEUTICAL SERVICES INC's 10-Q filed 2026-07-23 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 FY2026 net sales grew 13.8% YoY to $872.3M on 16.6% Proprietary Products growth (HVP demand), lifting gross margin 2.0pts to 37.7% despite a ~$7M cyber-incident hit to West Vantage.

Biggest Revenue Drivers

Proprietary Products$722.6M+16.6% YoY

Driven by strong customer demand for HVP components and delivery devices, including Biologics and GLP-1 products, plus sales price increases

West Vantage$149.7M+2.0% YoY

Sales price increases and higher production volumes, partially offset by ~$7M revenue impact from May 2026 cyber-incident production downtime

Biggest Revenue Drivers

Total revenue: $872.3M+13.8% YoY

Proprietary Products$722.6M+16.6% YoY

Driven by strong customer demand for HVP components and delivery devices, including Biologics and GLP-1 products, plus sales price increases

Within Proprietary Products

HVP Components49% of net sales+18.4% organic (ex-FX)

Continued strong customer demand for Biologics and GLP-1 products plus sales price increases

HVP Delivery Devices15% of net sales+29.2% organic (ex-FX)

Customer demand for self-injection devices, particularly SmartDose 3.5mL ahead of July 2026 divestiture closing

West Vantage$149.7M+2.0% YoY

Sales price increases and higher production volumes, partially offset by ~$7M revenue impact from May 2026 cyber-incident production downtime

Largest Expense Items

Cost of goods and services sold$543.1M

Rose with sales volume, partially offset by favorable HVP mix and price increases that expanded gross margin

Selling, general and administrative expenses$117.6M+22.6% YoY

Higher salaries/incentive compensation and nonrecurring professional fees tied to legal matters, the May 2026 cyber incident, and SmartDose M&A activity

Research and development$19.7M+3.1% YoY

Investment in primary injectables, elastomeric components, and drug containment/self-injection systems

Margins: Consolidated gross margin rose 2.0 points to 37.7%, led by favorable HVP mix (including GLP-1) and price increases in Proprietary Products, partially offset by West Vantage margin decline from cyber-incident-related production inefficiencies and plant cost inflation.

Watch Items from the Filing

In May 2026 the company suffered a material cybersecurity attack with data exfiltration and system encryption, disrupting global operations and cutting West Vantage revenue by ~$7M from production downtime.
Biologics customers represented 43% of net sales in Q2 2026, up from 38% a year ago, increasing revenue concentration in a single end-market.
A securities class action (filed May 2025) alleging Exchange Act violations remains in early stages, with a motion to dismiss pending; the company cannot yet estimate potential losses.
The company completed the sale of its SmartDose 3.5mL business to AbbVie on July 1, 2026 for ~$136M cash, expecting a $55-60M pre-tax gain in Q3 2026 but removing a growing product line.
The company repurchased $454.3M of stock in six months under a new $1.0B program authorized in February 2026, with $545.7M remaining as of June 30, 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$872.3M

Net Income

Q2 2026

$154.0M

Free Cash Flow

Q2 2026

$80.8M

Operating Margin

Q2 2026

20.5%

ROIC

Q2 2026

22.4%

D/E Ratio

Q2 2026

0.07

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+6.3% YoY

$3.07BFY 2025

FY22 $2.89BFY23 $2.95BFY24 $2.89BFY25 $3.07B

Net Income

+0.2% YoY

$493.7MFY 2025

FY22 $585.9MFY23 $593.4MFY24 $492.7MFY25 $493.7M

Operating Income

+2.6% YoY

$584.9MFY 2025

FY22 $734.0MFY23 $676.0MFY24 $569.9MFY25 $584.9M

EPS (Diluted)

+1.5% YoY

$6.79FY 2025

FY22 $7.73FY23 $7.88FY24 $6.69FY25 $6.79

Total Assets

+17.2% YoY

$4.27BFY 2025

FY22 $3.62BFY23 $3.83BFY24 $3.64BFY25 $4.27B

Total Debt

+0.1% YoY

$202.8MFY 2025

FY22 $211.1MFY23 $340.8MFY24 $202.6MFY25 $202.8M

Op. Cash Flow

+15.5% YoY

$754.8MFY 2025

FY22 $724.0MFY23 $776.5MFY24 $653.4MFY25 $754.8M

Free Cash Flow

+69.6% YoY

$468.9MFY 2025

FY22 $439.4MFY23 $414.5MFY24 $276.4MFY25 $468.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$3.07B +6.3%	$2.89B -1.9%	$2.95B +2.2%	$2.89B +2.0%	$2.83B +31.9%	$2.15B
Net Income	$493.7M +0.2%	$492.7M -17.0%	$593.4M +1.3%	$585.9M -11.5%	$661.8M +91.2%	$346.2M
Operating Income	$584.9M +2.6%	$569.9M -15.7%	$676.0M -7.9%	$734.0M -2.4%	$752.3M +84.9%	$406.9M
EPS (Diluted)	$6.79 +1.5%	$6.69 -15.1%	$7.88 +1.9%	$7.73 -10.8%	$8.67 +89.7%	$4.57
Total Assets	$4.27B +17.2%	$3.64B -4.9%	$3.83B +5.9%	$3.62B +9.1%	$3.31B +18.6%	$2.79B
Total Debt	$202.8M +0.1%	$202.6M -40.6%	$340.8M +61.4%	$211.1M -38.2%	$341.4M +31.4%	$259.8M
Operating Cash Flow	$754.8M +15.5%	$653.4M -15.9%	$776.5M +7.3%	$724.0M +24.0%	$584.0M +23.6%	$472.5M
Free Cash Flow	$468.9M +69.6%	$276.4M -33.3%	$414.5M -5.7%	$439.4M +32.9%	$330.6M +10.9%	$298.1M

AI Insight: WST Financial Trends

Revenue growth accelerating to 3.2% YoY in Q2 2026, but operating cash flow collapsed to $124M despite margin expansion.

• Revenue grew from $698M (Q1 2025) to $872M (Q2 2026), +24.9% over 5 quarters. Q2 2026 up 3.2% YoY vs Q2 2025.

• Operating margin expanded from 15.3% (Q1 2025) to 20.5% (Q2 2026), 520bp improvement over five quarters.

• Operating cash flow fell 30% from $197M (Q3 2025) to $124M (Q2 2026), despite higher operating income and net income.

⚠ Working capital deterioration: OpCF weakness persists despite margin expansion. Monitor Q3 2026 cash conversion.

⚠ Equity spiked to $3,176M (Q4 2025), then moderated to $2,990M (Q2 2026). Debt stable at $203M; leverage remains conservative.

AI Insight: WST Ratio Trends

WST rebounded sharply in Q2 2026 with ROE hitting 20.6% and ROIC reaching 22.4%, recovering from Q4 2025 lows after a Q1 2025 margin crash.

• Operating margin recovered to 21.0% in Q1 2026 and 20.5% in Q2 2026, versus Q1 2025 trough of 15.3%.

• ROIC expanded to 22.4% in Q2 2026, highest in dataset, from 18.5% low in Q4 2025.

• Leverage stable: D/E remained 0.07 in latest quarter, matching historical norms.

⚠ Q1 2025 saw severe margin compression (OpMargin 15.3%, ROE 13.4%)—cause and sustainability of recovery unclear.

⚠ NPM volatility: ranged 12.9%–18.2% over period; Q2 2026 stabilized at 17.6% after Q4 2025 weakness.

Get alerted when WST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for WEST PHARMACEUTICAL SERVICES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WST

BlackRock, Inc.
$2.4B6,651,784 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.7B4,613,134 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.4B4,015,766 sh
FMR LLC
$1.3B3,574,816 sh
STATE STREET CORP
$1.2B3,348,698 sh
Artisan Partners Limited Partnership
$865.8M2,411,792 sh
Bank of New York Mellon Corp
$733.7M2,043,823 sh
GENERATION INVESTMENT MANAGEMENT LLP
$728.2M2,028,322 sh
GEODE CAPITAL MANAGEMENT, LLC
$680.6M1,903,279 sh
T. Rowe Price Investment Management, Inc.
$648.0M1,805,019 sh

Fund	Value	Shares
BlackRock, Inc.	$2.4B	6,651,784
VANGUARD CAPITAL MANAGEMENT LLC	$1.7B	4,613,134
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.4B	4,015,766
FMR LLC	$1.3B	3,574,816
STATE STREET CORP	$1.2B	3,348,698
Artisan Partners Limited Partnership	$865.8M	2,411,792
Bank of New York Mellon Corp	$733.7M	2,043,823
GENERATION INVESTMENT MANAGEMENT LLP	$728.2M	2,028,322
GEODE CAPITAL MANAGEMENT, LLC	$680.6M	1,903,279
T. Rowe Price Investment Management, Inc.	$648.0M	1,805,019

Companies Similar to WST

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 29 shared holders

Capital Research Global Investors WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Liontrust Investment Partners LLP

ZTS

Zoetis Inc.

AI score

Very similar · 22 shared holders

STATE FARM MUTUAL AUTOMOBILE INSURANCE CO Epoch Investment Partners, Inc.Capital Research Global Investors

PODD

INSULET CORP

AI score

Very similar · 33 shared holders

T. Rowe Price Investment Management, Inc.Artisan Partners Limited Partnership Capital Research Global Investors

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 22 shared holders

Artisan Partners Limited Partnership Longview Partners (Guernsey) LTD LORD, ABBETT & CO. LLC

STE

STERIS plc

AI score

Very similar · 30 shared holders

GENERATION INVESTMENT MANAGEMENT LLP Findlay Park Partners LLP ROYAL LONDON ASSET MANAGEMENT LTD

DGX

QUEST DIAGNOSTICS INC

AI score

Very similar · 24 shared holders

APG Asset Management N.V.Candriam S.C.A.AVIVA PLC

LABCORP HOLDINGS INC.

AI score

Very similar · 25 shared holders

LORD, ABBETT & CO. LLC AMI ASSET MANAGEMENT CORP abrdn plc

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Very similar · 28 shared holders

Holocene Advisors, LP Boston Trust Walden Corp National Pension Service

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WST on your watchlist

Track score changes the day WEST PHARMACEUTICAL SERVICES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WST a good stock to buy?

13F Pro's AI-powered analysis of WEST PHARMACEUTICAL SERVICES INC (WST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WST are available on the WST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. WST is classified as a large company.

Which hedge funds own WST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of WEST PHARMACEUTICAL SERVICES INC's investment landscape.